Tuesday, 05 July 2022

AstraZeneca India's NSCLC drug Tagrisso receives marketing approval

10 March 2021 | News

A once daily oral pill, when given in patients of lung cancer, whose tumour have specific mutation called EGFR mutation and who have undergone surgical removal of the lung tumour

Source credit: Shutterstock

Source credit: Shutterstock

AstraZeneca Pharma India Limited has announced that it has received marketing approval for Tagrisso ® (Osimertinib) for adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC), whose tumours have epidermal growth factor receptor (EGFR) mutations.

Gagandeep Singh Bedi, Managing Director, Astrazeneca India, said “The regulatory approval of Tagrisso® (Osimertinib) in India will provide better medicine for the management of non-small cell lung cancer and help patients attain a better quality of life.”

Osimertinib, a once daily oral pill, when given in patients of lung cancer, whose tumour have specific mutation called EGFR mutation and who have undergone surgical removal of the lung tumour, has shown to decrease the risk of  cancer recurrence by nearly 83 per cent in the ADAURA® clinical trial in early stage lung cancer patients.

Osimertinib is the first targeted oral treatment option to show such a significant benefit in terms of cancer free survival in early lung cancers with EGFRm positivity. Cancer spread to the brain and other organs is one of the important cause of recurrence in early stage lung cancer. Osimertinib has shown to decrease the chances of cancer spreading to the brain & other distant organs.

Gagandeep Singh Bedi, Managing Director, Astrazeneca India, said “AstraZeneca has always been and will continue to bring forward world-class treatment solutions for non-communicable diseases. The regulatory approval of Tagrisso® (Osimertinib) in India will provide better medicine for the management of Non-Small Cell Lung Cancer and help patients attain a better quality of life.”

Dr Anil Kukreja, Vice President – Medical Affairs & Regulatory, AstraZeneca India said, “The approval of Osimertinib  as an adjuvant treatment for EGFRm NSCLC in India, will provide the much needed treatment choice for patients in early lung cancers with EGFRm positivity. The approval will provide oncologists with potential therapeutic option to be given with curative intent to eligible select early lung cancer patients.”

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account